Brand name: Perjeta ^TM

Active ingredients: pertuzumab

What it is used for

Early Breast Cancer Perjeta is indicated in combination with trastuzumab and chemotherapy for:,- the neoadjuvant treatment of patients with HER2-positive inflammatory or locally advanced, or early stage (either > 2 cm in diameter or node positive) breast cancer as part of a complete treatment regimen for early breast cancer,-the adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence.,Metastatic Breast Cancer,Perjeta is indicated in combination with trastuzumab and docetaxel for patients with metastatic HER2-positive breast cancer who have not received prior anti-HER2 therapy or chemotherapy for their metastatic disease.

How to take it

The way to take this medicine is: Intravenous Infusion.

Store at 2 to 8 degrees Celsius
Protect from Light
Do not Freeze
Do not Shake
Shelf lifetime is 24 Months.

You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.

Always read the label. If symptoms persist see your healthcare professional.

Visual appearance

Clear to opalescent, colourless to slightly brownish solution

Do I need a prescription?

This medicine is available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.

Pregnant or planning a pregnancy?

For the active ingredient pertuzumab

You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.